Post on 24-Jul-2020
As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over a nearly 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society.
Business Activities
Vision-driven / Customer Perspective / Creativity and Innovation / Employee Growth / Harmony with Society
Strategic Vision
Organizational Principles
Aiming to Become a “Specialized Pharmaceutical Company with a Global Presence”
Integrity and Trust / Customer-oriented Thinking / Expertise / Innovation / Collaboration and CooperationIndividual Action Principles
Guided by Santen’s Values in all our business activities, Santen strives to achieve our long-term strategic vision toward the year 2020. We provide products and services reflecting the needs of patients and medical personnel worldwide.
“Exploring the secrets and mechanisms of nature in order to contribute to people’s health”
We think carefully about what is essential, decide clearly what we should do, and act quickly.
By focusing on ophthalmology, Santen develops unique scientific knowledge and organizational capabilities that contribute to the well-being of patients, their loved ones and consequently to society.
COMPANY PROFILE
Santen’s original interpretation of a passage from chapter 22 of Zhongyong (The Doctrine of the Mean) by Confucius, meaning
Mission Statement
Values
Santen’s Values and Mission Statement
Develop products that meet true customer needs swiftly
Transform Japan business for further growth
Accelerate business expansion in Asia and promote market entry in Western Europe / U.S.
Establish global supply and quality systems
Strengthen organization and talent capabilities to promote creation and innovation
Five Policies to Achieve Vision 2020
92.3%Year ended March 31, 2019
Glaucoma / ocular hypertension
Disease area Project Compound /Product Original / Licensor Region / Country
Kerato conjunctival disease
Cataract
Retinal / uveal disease
Allergy
Myopia
tafluprost/timolol maleateomidenepag isopropylsepetaprostglaucoma implant devicelatanoprost
diquafosol sodium
sirolimuscarotuximab
ciclosporinepinastine hydrochloride
atropine sulfate
intraocular lens
Co-development with AGCCo-development with Ube IndustriesONO PHARMACEUTICALOriginalOriginal
Merck Sharp & Dohme Corp. (U.S.)
OriginalTRACON Pharmaceuticals
OriginalNippon Boehringer Ingelheim
Singapore Health Services, Nanyang Technological University
Oculentis
ChinaU.S. / Japan / AsiaU.S. / JapanU.S. / Europe Europe / Asia
China
U.S. / Japan / Europe / AsiaU.S.
Europe / Asia / OthersJapan
Japan / Asia
Japan
Business Overview
#2
Over-the-CounterPharmaceuticals
Share ofJapanese Market
Prescription Pharmaceuticals(Revenue Composition)
Medical Devices Others
Financial Information Santen Pharmaceutical Co., Ltd., and Subsidiaries (IFRS) years ended March 31, 2019
Corporate Information
Pipeline / Product Development Status ( As of May 9, 2019 )
Revenue
Core operating profit
Core net profit for the year
Operating profit
Net profit for the year
Corporate HeadquartersSanten Pharmaceutical Co., Ltd.Grand Front Osaka Tower A, 4-20 Ofuka-cho Kita-ku, Osaka 530-8552, JapanTEL: +81-6-6321-7000
Established 1890Incorporated 1925Paid-in Capital ¥8,252 million (As of Mar 31, 2019)Number of Employees 4,073 (As of Mar 31, 2019)Representatives Akira Kurokawa (Chairman & CEO)Stock Exchange Listings Tokyo (Ticker code : 4536)
SubsidiariesJapan : 3 subsidiaries U.S. : 7 subsidiaries EMEA : 10 subsidiaries, Santen SA (EMEA Headquarters)Asia : 11 subsidiaries
Laboratories and PlantsNara Research and Development Center Noto Plant, Shiga Product Supply CenterSuzhou Plant, Tampere Plant
234,026
48,230
36,092
45,098
31,943
EPS
R&D expenses
Depreciation and amortization
Cash dividends, applicable to the period
Thousands of U.S. Dollars Thousands of U.S. Dollars
31.4% 20.6% 10.2% 4.0% 11.1%
*1 Source: Copyright © 2019 IQVIA. IMS-JPM 2018-2019; Santen analysis based on IQVIA data. Reprinted with permission.
*2 Market share and market position in Japanese for the fiscal year ended March 31, 2019. Source: Santen Pharmaceutical Co., Ltd.
*3 Santen discloses information on a core basis to better express its recurring business performance. Financial information on a core basis excludes certain gains and expenses from IFRS results on a full basis.
Overseas sales to revenue Core operating profit margin*3 R&D expenses to revenue Revenue growth Return on equity (ROE)
*2 234.0
FY2018Revenue
billion yen
2,108,535
434,547
325,185
406,322
287,798
¥ 78.67
23,759
10,969
¥ 26
$ 0.71
214,061
98,831
$ 0.23
Please refer to the Pipeline sectionon the Company’s website for details.
Countries in WhichProducts Are Sold
Approximately
60Prescription Ophthalmic
Pharmaceuticals Share of
Japanese Market
1# *1
Production Sites 4 plantsNoto, Shiga (Japan),
Suzhou (China) and Tampere (Finland)
US dollar amounts have been translated for convenience only from yen at the rate of ¥110.99 to US $1.00,the exchange rate prevailing on March 31, 2019
DE-111DE-117DE-126DE-128DE-130A (Catioprost)
DE-089
DE-109DE-122
DE-076C (Vekacia)DE-114A
DE-127
MD-16
Millions of YenMillions of Yen